Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials
call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or
email cancerclinicaltrials@bsd.uchicago.edu.

A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)

Official Title

A Phase Ib Multi-Cohort Trial of MK-3475 (Pembrolizumab) in Subjects With Hematologic Malignancies

Principal Investigator

Kline, Justin

Brief Summary

The purpose of this trial is to evaluate the safety, tolerability, and efficacy of
pembrolizumab (MK-3475) in hematologic malignancies. The primary study hypotheses are that
treatment with pembrolizumab will result in a clinically meaningful improvement in overall
response and complete remission.